Fomepizole treatment of ethylene glycol poisoning in an infant

Carl R. Baum*, Craig B. Langman, Elif E. Oker, Craig A. Goldstein, Sandra R. Aviles, Jasmin K. Makar

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


The enzyme alcohol dehydrogenase metabolizes ingested ethylene glycol (EG) to the toxic compounds glycolic and oxalic acids. Renal failure, acidosis, hypocalcemia, and death may follow. Traditional treatment of EG poisoning may require ethanol, a competitive substrate of alcohol dehydrogenase, and hemodialysis, that removes both EG and its toxic metabolites. A new alcohol dehydrogenase inhibitor, fomepizole (4-methylpyrazole), was approved in 1997 for patients at least 12 years old with suspected or confirmed EG poisoning. Fomepizole has not been studied adequately in the pediatric population. We present a case of an 8-month-old male infant who drank up to 120 mL of EG and developed acidosis and oxalate crystalluria. He was treated with fomepizole and hemodialysis. Even after the completion of hemodialysis, fomepizole appeared to effectively block the production of EG toxic metabolites and to allow the resolution of acidosis; the patient recovered within 48 hours. This is the first report of fomepizole treatment of EG poisoning in an infant.

Original languageEnglish (US)
Pages (from-to)1489-1491
Number of pages3
Issue number6
StatePublished - 2000


  • 4-methylpyrazole
  • Child
  • Ethylene glycol
  • Fomepizole
  • Hemodialysis
  • Infant
  • Pediatrics
  • Poisoning

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Fomepizole treatment of ethylene glycol poisoning in an infant'. Together they form a unique fingerprint.

Cite this